ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Expression and Therapeutic Potential of SOX9 in Chordoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels.Frontiers in oncology · 2022Pooled it
- Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.Targeted oncology · 2021Pooled it
- SOX9, GATA3, and GATA4 Overexpression in Liposarcomas: Insights into the Molecular Biology of Adipocytic Sarcomas.International journal of molecular sciences · 2025Article
- Immune Checkpoint Therapy for Thymic Carcinoma.Cancers · 2025Review
- Developmental gene expression in skull-base chordomas and chondrosarcomas.Journal of neuro-oncology · 2025Article
- Article
- N6-methyladenosine-modified circTEAD1 stabilizes Yap1 mRNA to promote chordoma tumorigenesis.Clinical and translational medicine · 2024Article
- CRISPRingCancers · 2024Review
- Mapping the landscape of genetic dependencies in chordoma.Nature communications · 2023Article
- SOX9 negatively regulates the RLR antiviral signaling by targeting MAVS.Virus genes · 2022Article
- Extracellular ATP promotes breast cancer chemoresistance via HIF-1α signaling.Cell death & disease · 2022Article
- Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas.Blood · 2022Article
- Selinexor inhibits growth of patient derived chordomasFrontiers in oncology · 2022Article
- CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway.Cancer cell international · 2021Article
- Review
- GSK-3β Regulates the Expression of P21 to Promote the Progression of Chordoma.Cancer management and research · 2021Article
- SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis.Molecular cancer research : MCR · 2020Article
- SOX9 Knockout Induces Polyploidy and Changes Sensitivity to Tumor Treatment Strategies in a Chondrosarcoma Cell Line.International journal of molecular sciences · 2020Article
- T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.Cell proliferation · 2020Article
- Extracellular ATP promotes breast cancer invasion and chemoresistance via SOX9 signaling.Oncogene · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.